The company says a trial met its goal to prevent melanoma recurrence.

Moderna announced that a trial for its cancer vaccine met its goal of preventing melanoma recurrence. This development marks a significant step in the company's efforts to advance cancer treatment.

Opinion | Moderna’s Road to a Cancer Vaccine

Drugmaker’s melanoma shot developed with Merck delivers positive outcome in late-stage trial

Moderna's shares nearly tripled following positive results from a late-stage trial of its melanoma vaccine, developed in collaboration with Merck. The drugmaker's skin cancer shot demonstrated successful outcomes in the trial.

Moderna shares nearly triple on skin cancer vaccine success

The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.

Moderna's and Merck's personalized mRNA vaccine, when combined with Merck's Keytruda, demonstrated significant efficacy in reducing the risk of melanoma recurrence in a late-stage trial involving over 1,100 patients, leading to a surge in their stock prices.

Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring

A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.

Moderna's stock surged 131% following a Phase 3 trial victory against the standard of care for cancer treatment, resulting in a doubling of its shares and causing short sellers to incur losses of $4.8 billion.

Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means

Optimism about a potential breakthrough in personalised cancer treatment has sent shares in Moderna soaring by nearly 100%. File image: iStock

Moderna's share price has surged by nearly 100% due to optimism surrounding a potential breakthrough in personalized cancer treatment.

Moderna's share price nearly doubles on hopes of cancer treatment breakthrough

Moderna's successful trial for its melanoma vaccine marks a significant milestone in its cancer treatment efforts, further boosting investor confidence and solidifying its position in the biotech sector.

Moderna Advances Cancer Vaccine Development

Moderna's shares have now surged 131% following a Phase 3 trial victory, doubling its stock price and resulting in significant losses for short sellers, totaling $4.8 billion.

Moderna's Stock Surges Further on Trial Success

ارتفعت أسهم موديرنا بنسبة تقارب 100% بعد النتائج الإيجابية من تجربة متقدمة للقاح الميلانوما المخصص الذي تم تطويره بالتعاون مع ميرك. وقد قلل اللقاح بشكل كبير من خطر عودة الميلانوما لدى أكثر من 1100 مريض، مما أدى إلى زيادة ثقة المستثمرين وارتفاع أسعار الأسهم.

Las acciones de Moderna casi se triplicaron tras los resultados positivos de un ensayo de fase avanzada de su vacuna personalizada de ARNm contra el melanoma, desarrollada con Merck. La vacuna redujo significativamente el riesgo de recurrencia del melanoma en más de 1,100 pacientes, lo que llevó a un aumento en la confianza de los inversores y en los precios de las acciones.

Les actions de Moderna ont presque triplé après des résultats positifs d'un essai de phase avancée de son vaccin personnalisé à ARNm contre le mélanome, développé avec Merck. Le vaccin a considérablement réduit le risque de récidive du mélanome chez plus de 1 100 patients, entraînant une hausse de la confiance des investisseurs et des prix des actions.